Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres
- 19 October 2020
- journal article
- letter
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56 (3) , 738-740
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and managementAmerican Journal of Hematology, 2020
- Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trialBritish Journal of Haematology, 2017
- VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trialBlood, 2016
- Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myelomaLeukemia, 2015
- Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaLeukemia, 2015
- CyBorD induction therapy in clinical practiceBone Marrow Transplantation, 2015
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaBlood, 2012
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyThe Lancet Oncology, 2011
- Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myelomaBlood, 2010
- The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)Haematologica, 2007